CJC-1295, Mod GRF(1-29), and Why Product Identity Matters

CJC-1295 was designed as a long-acting GHRH analogue

CJC-1295 contains substitutions that improve stability relative to native GHRH. The version developed with a drug-affinity-complex moiety can bind albumin and extend exposure. Human studies of defined CJC-1295 forms examined growth-hormone and IGF-1 responses.

Mod GRF(1-29) is a different description

Modified GRF(1-29) generally refers to a 29-amino-acid GHRH analogue with stabilizing substitutions but no albumin-binding DAC. It has a shorter expected exposure profile. Although the molecules share a pathway, they are not automatically the same compound.

Marketplace shorthand creates scientific errors

The phrase CJC-1295 no DAC is frequently used for Mod GRF(1-29). If a supplier uses that phrase without sequence, molecular mass, and modification data, literature cannot be assigned confidently. A paper on DAC-modified CJC-1295 may be irrelevant to a short-acting analogue.

Identity must be resolved analytically

A defensible listing should provide the exact sequence, termini, molecular formula, theoretical mass, counterion, and mass-spectrometric confirmation. Naming alone is not an analytical result.

Safety interpretation depends on the actual molecule

FDA has described serious adverse events and characterization concerns associated with CJC-1295 in the compounding context. Exposure duration, aggregation, impurities, and endocrine effects may differ across forms.

This article is provided for scientific and educational purposes. It does not describe or recommend human or veterinary use. Research findings may be limited by study design, model selection, material identity, sample size, or lack of independent replication.